Citation:Delbaldo C, Michiels S, Rolland E, Syz N, Soria JC, Le Chevalier T, et al 2007

From Cancer Guidelines Wiki

Citation


Delbaldo C, Michiels S, Rolland E, Syz N, Soria JC, Le Chevalier T, et al. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev 2007 Oct 17;(4):CD004569 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17943820.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Delbaldo C, Michiels S, Rolland E, Syz N, Soria JC, Le Chevalier T, et al 2007What is the optimal systemic therapy for stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Delbaldo C, Michiels S, Rolland E, Syz N, Soria JC, Le Chevalier T, et al 2007 2Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Delbaldo C, Michiels S, Rolland E, Syz N, Soria JC, Le Chevalier T, et al 2007 3Are three chemotherapy agents better than two chemotherapy agents for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Delbaldo C, Michiels S, Rolland E, Syz N, Soria JC, Le Chevalier T, et al 2007 4What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Are three chemotherapy agents better than two chemotherapy agents for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Are three chemotherapy agents better than two chemotherapy agents for treatment of stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. Are three chemotherapy agents better than two chemotherapy agents for treatment of stage IV inoperable NSCLC?
  2. Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?
  3. What is the optimal systemic therapy for stage IV inoperable NSCLC?
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:Delbaldo_C,_Michiels_S,_Rolland_E,_Syz_N,_Soria_JC,_Le_Chevalier_T,_et_al_2007&oldid=21620"